Evotec publishes DDup 9 – Evotec’s iPSC-based TargetRD programme

  •  The 9th edition of DDup is dedicated to our unique and innovative iPSC-based drug discovery programme TargetRD (Retinal Disease), which we have developed in collaboration with our colleagues from the Centre for Regenerative Therapies TU Dresden. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-publishes-ddup-9—evotecs-ipsc-based-targetrd-programme-5951

    Du magst vielleicht auch